Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 623.

https://doi.org/10.1182/blood-2023-179160

Published: 2023

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

Natalia Buenache Cuenda, Hipolito Nicolas Cuesta Hernández, Alicia Giménez Sánchez, Laura Carneros Blanco, Juan Manuel Rosa-Rosa, Yanira Ruiz-Heredia, Enrique Revilla, Seungbin Han, Umair Munawar, Inmaculada Rapado, Rosa Ayala, K. Martin Kortüm, Antonio Valeri, Santiago Barrio, Joaquin Martinez Lopez, Larissa Haertle

Blood (2023) 142 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2023-184824

Published: 2023

Journal Articles

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Blood (2023) 142 (Supplement 1): 2960.

https://doi.org/10.1182/blood-2023-189676

Published: 2023

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Irene Zamanillo, Santiago Barrio, Alejandro Martín-Muñoz, Sara Dorado, Ana K Ballesteros, Yanira Ruiz-Heredia, Margarita Rodriguez, Carolina Martinez-Laperche, Sandra Martín, Blanca Ferrer Lores, Ivan Martin Castillo, Inmaculada Rapado, Rosa Ayala, Joaquin Martinez-Lopez, Maria Teresa Cedena Romero

Blood (2023) 142 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2023-188600

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Blood (2023) 142 (Supplement 1): 3163.

https://doi.org/10.1182/blood-2023-188875

Published: 2023

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Justin M. Watts, Alessandro M. Vannucchi, Anthony M. Hunter, Brandon McMahon, Srinivas K. Tantravahi, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Emma Searle, Brandi N. Reeves, Prithviraj Bose, Rosa Ayala, Anna B. Halpern, Xuejun Chen, Lea M Burke, Feng Zhou, Fred Zheng, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 750.

https://doi.org/10.1182/blood-2023-179428

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Adolfo Jesús Sáez Marín, Gema Hernández-Ibarburu, Rafael Alonso Fernández, Jose Maria Sanchez Pina, Paula Lázaro Del Campo, Ana Jimenez Ubieto, Clara Cuellar, Andrea Tamayo Soto, Reyes Mas Babio, Lucia Medina, Maria Calbacho, Rosa Ayala, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 7064.

https://doi.org/10.1182/blood-2023-180923

Published: 2023

Journal Articles

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2023-180646

Published: 2023

Journal Articles

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Maria Poza Santaella, Rodrigo Íñiguez, Irene Zamanillo, Tycho S. Baumann, Antonia Rodriguez Izquierdo, Enrique Revilla, Sandra Gomez Rojas, Gloria Perez Segura, Pilar Martinez Sanchez, Carlos Grande, Pilar Sarandeses, Santiago Barrio, Maria Calbacho, Rosa Ayala, Joaquin Martinez-Lopez, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2023-189161

Published: 2023

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Lucía Pérez-Lamas, Juan Carlos Hernandez Boluda, Luis Felipe Casado Montero, Maria Teresa Gómez Casares, Rosa Ayala, Blanca Xicoy, Francisca Ferrer Marin, Guillermo Orti, Raquel De Paz Arias, Santiago Osorio Prendes, Raul Perez Lopez, Elvira Mora, Concepción Ruiz Nuño, Antonio Jimenez Velasco, Concepcion Boque, Magdalena Sierra Pacho, Joaquin Martinez Lopez, Valentin Garcia Gutierrez

Blood (2023) 142 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2023-184989

Published: 2023

Journal Articles

Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with Trinetx

Mario Rodríguez-Rodríguez, Nerea Castro-Quismondo, Denis Zafra-Torres, Alberto Blanco-Sánchez, Gema Hernandez-Ibarburu, Miguel Pedrera-Jimenez, Rosa Ayala, Joaquín Martínez-Lopez

Blood (2022) 140 (Supplement 1): 8540–8541.

https://doi.org/10.1182/blood-2022-160180

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 2270–2272.

https://doi.org/10.1182/blood-2022-163159

Published: 2022

Journal Articles

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase ( PSMC ) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket

Larissa Haertle, Hipolito Nicolas Cuesta Hernandez, Natalia Sofia Buenache, Michal Simicek, Renata Snaurova, Inmaculada Rapado, Nerea Martinez, Nieves López-Muñoz, Jose Maria Sanchez-Pina, Rafael Colmenares, Margarita Sanchez-Beato, Miguel Angel Piris, Ivan Plaza Menacho, Mehmet Kemal Samur, Nikhil C Munshi, Rosa Ayala, K. Martin Kortuem, Santiago Barrio, Joaquin Martinez-Lopez

Blood (2022) 140 (Supplement 1): 4318–4319.

https://doi.org/10.1182/blood-2022-158763

Published: 2022

Journal Articles

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Blood (2022) 140 (Supplement 1): 3422–3424.

https://doi.org/10.1182/blood-2022-166639

Published: 2022

NARROW

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient

A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years

Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with Trinetx

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase ( PSMC ) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket

Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only